Base de dados : MEDLINE
Pesquisa : D12.776.124.486.485.114.254.450.504 [Categoria DeCS]
Referências encontradas : 9201 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 921 ir para página                         

  1 / 9201 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449972
[Au] Autor:Sil A; Ravi MD; Patnaik BN; Dhingra MS; Dupuy M; Gandhi DJ; Dhaded SM; Dubey AP; Kundu R; Lalwani SK; Chhatwal J; Mathew LG; Gupta M; Sharma SD; Bavdekar SB; Rout SP; Jayanth MV; D'Cor NA; Mangarule SA; Ravinuthala S; Reddy E J
[Ad] Endereço:Shantha Biotechnics Private Limited - A Sanofi Company, Hyderabad, India. Electronic address: arijit.sil@sanofi.com.
[Ti] Título:Effect of prophylactic or therapeutic administration of paracetamol on immune response to DTwP-HepB-Hib combination vaccine in Indian infants.
[So] Source:Vaccine;35(22):2999-3006, 2017 05 19.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Vaccination is considered as the most cost effective method for preventing infectious diseases. Low grade fever is a known adverse effect of vaccination. In India, it is a common clinical practice to prescribe paracetamol either prophylactically or therapeutically to manage fever. Some studies have shown that paracetamol interferes with antibody responses following immunization. This manuscript reports the outcome of a post hoc analysis of data from a clinical trial of a pentavalent vaccine in Indian infants where paracetamol was not used or was used either as prophylaxis or for treatment of fever. METHODS: Pre and post vaccine antibody levels against Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenzae type B were assessed in no paracetamol and paracetamol groups. The paracetamol group was further divided into prophylactic and treatment groups. RESULTS: Similar rates of seroprotection/seroresponse for anti-D, anti-T, anti-wP, anti-PT, anti-HBs and anti-PRP were observed in all the groups. There was no clear tendency for difference in percentage seroprotection/seroresponse and geometric mean (GM) titers in any of the groups. CONCLUSION: The study found no evidence that paracetamol usage either as prophylactic or for treatment impact immunological responses to DTwP-HepB-Hib combination vaccine. [Clinical trial registry of India (study registration number CTRI/2012/08/002872)].
[Mh] Termos MeSH primário: Acetaminofen/uso terapêutico
Anticorpos Antibacterianos/sangue
Vacina contra Difteria, Tétano e Coqueluche/administração & dosagem
Vacina contra Difteria, Tétano e Coqueluche/imunologia
Vacinas Anti-Haemophilus/administração & dosagem
Vacinas Anti-Haemophilus/imunologia
Vacinas contra Hepatite B/administração & dosagem
Vacinas contra Hepatite B/imunologia
Imunidade Humoral/efeitos dos fármacos
[Mh] Termos MeSH secundário: Acetaminofen/administração & dosagem
Acetaminofen/efeitos adversos
Difteria/imunologia
Difteria/prevenção & controle
Vacina contra Difteria, Tétano e Coqueluche/efeitos adversos
Feminino
Febre/tratamento farmacológico
Febre/etiologia
Febre/prevenção & controle
Infecções por Haemophilus/etnologia
Infecções por Haemophilus/imunologia
Infecções por Haemophilus/prevenção & controle
Vacinas Anti-Haemophilus/efeitos adversos
Hepatite B/imunologia
Hepatite B/prevenção & controle
Anticorpos Anti-Hepatite B/sangue
Vacinas contra Hepatite B/efeitos adversos
Seres Humanos
Índia
Lactente
Masculino
Tétano/imunologia
Tétano/prevenção & controle
Vacinação
Vacinas Conjugadas/imunologia
Coqueluche/imunologia
Coqueluche/prevenção & controle
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Bacterial); 0 (Diphtheria-Tetanus-Pertussis Vaccine); 0 (DtwP-HepB-Hib vaccine); 0 (Haemophilus Vaccines); 0 (Hepatitis B Antibodies); 0 (Hepatitis B Vaccines); 0 (Vaccines, Conjugate); 362O9ITL9D (Acetaminophen)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  2 / 9201 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29198036
[Au] Autor:Hara J; Tanaka Y; Kaneko H; Itoh Y; Ikegaya H
[Ad] Endereço:Department of Forensic Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho, Kamigyo, Kyoto, 602-8566, Japan.
[Ti] Título:Detection of hepatitis B virus DNA and HBsAg from postmortem blood and bloodstains.
[So] Source:Arch Virol;163(3):633-637, 2018 Mar.
[Is] ISSN:1432-8798
[Cp] País de publicação:Austria
[La] Idioma:eng
[Ab] Resumo:A large number of accidental virus infections occur in medical and non-medical workers exposed to infectious individuals and materials. We evaluated whether postmortem blood and bloodstains containing hepatitis B virus (HBV) are infectious. HBV-infected blood and bloodstains were stored for up to 60 days at room temperature and subsequently screened for hepatitis B surface antigen (HBsAg) and HBV DNA. In addition, HBV-positive postmortem blood was added to a cell line and the production of HBV virions was examined over a period of 7 days. HBsAg and HBV DNA were detected in all samples stored for 60 days at room temperature. HBV-positive postmortem blood successfully infected the cell line and progeny viruses were produced for up to 6 days. Thus, it is crucial that due care is taken when handling not only living material infected with HBV, as well as other harmful viruses, but also blood or body fluids from cadavers or medical waste.
[Mh] Termos MeSH primário: DNA Viral/sangue
Anticorpos Anti-Hepatite B/sangue
Antígenos de Superfície da Hepatite B/sangue
Vírus da Hepatite B/isolamento & purificação
Hepatite B/sangue
[Mh] Termos MeSH secundário: Autopsia
Preservação de Sangue
Feminino
Células Hep G2
Hepatite B/prevenção & controle
Hepatite B/transmissão
Hepatite B/virologia
Vírus da Hepatite B/genética
Vírus da Hepatite B/imunologia
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Viral); 0 (Hepatitis B Antibodies); 0 (Hepatitis B Surface Antigens)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171204
[St] Status:MEDLINE
[do] DOI:10.1007/s00705-017-3665-x


  3 / 9201 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27776593
[Au] Autor:Iglecias LM; Puga MA; Pompílio MA; Teles SA; Croda J; Lima LA; Lago BV; Martins RM; Motta-Castro AR
[Ad] Endereço:Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.
[Ti] Título:Epidemiological study of hepatitis B virus among prisoners with active tuberculosis in Central Brazil.
[So] Source:Int J Tuberc Lung Dis;20(11):1509-1515, 2016 Nov.
[Is] ISSN:1815-7920
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Due to environmental and social conditions inherent to incarceration, tuberculosis (TB) and hepatitis B virus (HBV) are major diseases among prison inmates. OBJECTIVE: To determine overall and occult HBV infection (OBI) prevalence rates, risk factors and genotype distribution among inmates with active TB. STUDY DESIGN: A cross-sectional study was conducted among 216 inmates with active TB recruited at the largest prisons in Campo Grande, Mato Grosso do Sul, Central Brazil. The participants were interviewed and tested for the presence of serological markers for HBV infection. RESULTS: The overall prevalence of HBV infection (total hepatitis B core antibodies) was 10.2% (95%CI 6.2-14.2). HBV surface antigen (HBsAg) prevalence was 1.4% (3/216). HBV DNA was detected in all three HBsAg-positive samples and in 10.5% (2/19) of the anti-HBc-positive samples (OBI), giving a HBV-TB co-infection prevalence of 2.3% (5/216). A multivariate analysis of risk factors showed that history of sharing cutting instruments, length of incarceration and homosexual sex were associated with HBV infection. CONCLUSION: Our findings indicate that HBV remains an important public health concern among prison inmates and active TB-HBV co-infection needs to be addressed for effective treatment.
[Mh] Termos MeSH primário: Coinfecção/epidemiologia
Hepatite B/epidemiologia
Prisioneiros
Tuberculose/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Brasil/epidemiologia
Coinfecção/diagnóstico
Estudos Transversais
DNA Viral/isolamento & purificação
Estudos Epidemiológicos
Feminino
Hepatite B/diagnóstico
Anticorpos Anti-Hepatite B/sangue
Antígenos de Superfície da Hepatite B/sangue
Vírus da Hepatite B/isolamento & purificação
Seres Humanos
Masculino
Prevalência
Fatores de Risco
Fatores Socioeconômicos
Tuberculose/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Viral); 0 (Hepatitis B Antibodies); 0 (Hepatitis B Surface Antigens)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  4 / 9201 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457830
[Au] Autor:Costa JEF; Morais VMS; Gonçales JP; Silva DM; Coêlho MRCD
[Ad] Endereço:Health Sciences Center, Federal University of Pernambuco, Av. Prof. Moraes Rego, 1235, Cidade Universitária, 50670-901, Recife, Pernambuco, Brazil. Electronic address: joanne_ferraz@yahoo.com.br.
[Ti] Título:Prevalence and risk factors for hepatitis B and C viruses in patients with leprosy.
[So] Source:Acta Trop;172:160-163, 2017 Aug.
[Is] ISSN:1873-6254
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:It has been reported a higher seroprevalence of HBV and HCV in leprosy patients than in the general population, but the reasons for these findings are not yet clear. On the other hand, there is evidence that these viruses may influence the onset of leprosy reactional episodes, an important cause of neurological sequelae. This study aimed to determine seroprevalence and risk factors for HBV and HCV in leprosy patients and to investigate its association with leprosy reactions. Patients attended from 2015 to 2016 at a Reference Center in Leprosy in Northeastern region of Brazil, were interviewed, had their records reviewed to investigate biological, clinical, behavioral and socioeconomic factors, and underwent blood sample collection. Biological samples were tested for HBV (HBsAg, anti-HBs and anti-HBs) and HCV (anti-HCV) serological markers by ELISA and, in anti-HCV positive samples, HCV RNA was screened by real time PCR. SPSS program was used to analyze the data. A total of 403 leprosy patients were included. Although anti-HBc was positive in 14.1%, there was no detection of HBsAg, which contradicts the hypothesis that leprosy patients have immune deficit that make them more prone to chronic HBV infection. Multibacillary leprosy (0.057), health-related work (0.011) and lower educational level (0.035) were associated with anti-HBc positivity. Anti-HCV was positive in 0.5%, with no detection of HCV RNA. No association was identified between anti-HCV and the epidemiological analyzed factors. There was also no association of anti-HBc or anti-HCV with type 1 or type 2 leprosy reactions. Thus, the seroprevalence of HBV and HCV in leprosy patients was similar to that of the general population of Northeastern region of Brazil, and no association of HBV or HCV with leprosy reactions was observed.
[Mh] Termos MeSH primário: Hepatite B/complicações
Hepatite B/virologia
Hepatite C/complicações
Hepatite C/virologia
Hanseníase/complicações
[Mh] Termos MeSH secundário: Adulto
Idoso
Biomarcadores/sangue
Brasil/epidemiologia
Ensaio de Imunoadsorção Enzimática
Feminino
Hepacivirus/isolamento & purificação
Anticorpos Anti-Hepatite B
Antígenos de Superfície da Hepatite B
Vírus da Hepatite B/isolamento & purificação
Anticorpos Anti-Hepatite C
Seres Humanos
Hanseníase/virologia
Masculino
Meia-Idade
Prevalência
Reação em Cadeia da Polimerase em Tempo Real
Fatores de Risco
Estudos Soroepidemiológicos
Testes Sorológicos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Hepatitis B Antibodies); 0 (Hepatitis B Surface Antigens); 0 (Hepatitis C Antibodies)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  5 / 9201 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Lampe, Elisabeth
Texto completo SciELO Brasil
[PMID]:29211108
[Au] Autor:Portilho MM; Nabuco LC; Villela-Nogueira CA; Brandão-Mello CE; Pilotto JH; Flores GL; Lewis-Ximenez LL; Lampe E; Villar LM
[Ad] Endereço:Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Hepatites Virais, Rio de Janeiro, RJ, Brasil.
[Ti] Título:Detection of occult hepatitis B in serum and oral fluid samples.
[So] Source:Mem Inst Oswaldo Cruz;113(1):62-65, 2018 Jan.
[Is] ISSN:1678-8060
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:In occult hepatitis B infection (OBI), hepatitis B virus DNA (HBV DNA) can be detected in serum samples; however, oral fluid collection for detection of HBV DNA has not yet been explored, despite the availability of collection devices. Serum and oral fluid samples from 45 hepatitis B core antibody (anti-HBc)-positive patients were collected for the amplification of the HBV polymerase gene. HBV DNA was detected in five serum and four oral fluid samples (the detection limit for oral fluid was 1.656 log IU/mL in paired serum). In conclusion, simple methodologies of sample collection and in-house polymerase chain reaction (PCR) allowed detection of HBV DNA, and these could be used to improve the diagnosis of OBI, especially in locations with limited resources.
[Mh] Termos MeSH primário: DNA Viral/análise
Anticorpos Anti-Hepatite B/análise
Antígenos de Superfície da Hepatite B/análise
Vírus da Hepatite B/genética
Hepatite B/diagnóstico
Saliva/virologia
[Mh] Termos MeSH secundário: Adulto
Idoso
DNA Viral/sangue
Feminino
Vírus da Hepatite B/isolamento & purificação
Seres Humanos
Masculino
Meia-Idade
Reação em Cadeia da Polimerase
Carga Viral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Viral); 0 (Hepatitis B Antibodies); 0 (Hepatitis B Surface Antigens)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE


  6 / 9201 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28743234
[Au] Autor:Ganczak M; Korzen M; Jurewicz A; Szych Z
[Ad] Endereço:Department of Epidemiology and Management, Pomeranian Medical University, Zolnierska 48, 71-210, Szczecin, Poland. mganczak@pum.edu.pl.
[Ti] Título:A cross-sectional sero-survey on preoperative HBV vaccination policy in Poland.
[So] Source:BMC Infect Dis;17(1):515, 2017 07 25.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: A two-dose preoperative vaccination schedule against HBV has been the widely accepted policy in Poland. However, its effectiveness has not yet been assessed. OBJECTIVE: To evaluate a two-dose preoperative HBV vaccination policy by an assessment of the proportion of patients who don't present a protective level of anti-HBs (<10.0 mIU/ml). METHODS: Consecutive patients from surgical/gynecologic wards of 12 randomly selected hospitals in West Pomerania, Poland, hospitalized between 2010 and 2013, vaccinated against HBV with a two-dose regimen, were asked to complete an anonymous questionnaire. Serum samples were assayed for anti-HBs with the use of third-generation testing methods. To compare sensitivity versus specificity across a range of values for the ability to predict a dichotomous outcome (a protection against HBV infection) a Receiver operating characteristic (ROC) curve was determined. RESULTS: There were 193 patients, 58.5% women, median age 52 years. Almost a half (46.0%) of the patients were operated on within 0-60 days of taking the second vaccine dose, 16.2% - 61-180 days after, 37.8% >180 days after. Anti-HBs titer was below a protective level in 49.2% of participants (0.0 mIU/ml in 17.8%, 0.1-9.9 mIU/ml in 31.4%); none of them were aware of this fact. Age ≤ 52 years (OR = 1.89) and having surgery more than 37.5 days after HBV vaccination (OR = 2.70) were associated with greater odds of being protected against HBV infection through vaccination. For the time frame between the second dose implementation and surgery 23 days, a sensitivity of 84% and specificity of 22% for obtaining protection against HBV infection was found, for the time frame >37.5 days - sensitivity remained high (80%), while specificity increased (41%); there was an apparent peek on the ROC curve between 38 and 60 day. In the group vaccinated 0-37.5 days before surgery, less patients had the protective level of anti-HBs titer than in vaccinated 38-60 days before surgery (32.3% vs 60.0%; p = 0.03). CONCLUSIONS: The success rate in achieving adequate immune protection with two dose HBV vaccination schedule in preoperatively vaccinated patients is relatively low, especially among those vaccinated less than five weeks prior to surgery. In more than a third of cases the standard three-dose regimen could have been implemented, as participants had time to complete a third dose. Current recommendations regarding a preoperative policy with a 2-dose vaccination schedule in Poland should be revised; the best time to perform surgery after the implementation of the second dose of vaccine in the context of patient protection against HBV infection would be between 38 and 60 days.
[Mh] Termos MeSH primário: Vacinas contra Hepatite B/uso terapêutico
Hepatite B/prevenção & controle
Cuidados Pré-Operatórios/métodos
[Mh] Termos MeSH secundário: Adulto
Estudos Transversais
Feminino
Anticorpos Anti-Hepatite B/sangue
Vacinas contra Hepatite B/administração & dosagem
Seres Humanos
Esquemas de Imunização
Masculino
Meia-Idade
Polônia
Curva ROC
Estudos Soroepidemiológicos
Inquéritos e Questionários
Vacinação/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Hepatitis B Antibodies); 0 (Hepatitis B Vaccines)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180120
[Lr] Data última revisão:
180120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1186/s12879-017-2607-2


  7 / 9201 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29095312
[Au] Autor:Kang FB; Wang L; Sun DX
[Ad] Endereço:aLiver Disease Diagnosis and Treatment Center, Bethune International Peace Hospital bOrthopedic Research Institute, the Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
[Ti] Título:Hepatitis B virus infection in an HBsAb-positive lymphoma patient who received chemotherapy: A case report.
[So] Source:Medicine (Baltimore);96(44):e8518, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Tumor chemotherapy could weaken the immune system of patients, which might enhance the body sensitivities to the exogenous pathogens, among which the hepatitis B virus (HBV) infection should be concerned because of the higher chances of infection and the severe outcomes, especially in East Asia. The titer level of hepatitis B surface antibody (HBsAb) higher than 10 IU/L is considered to offer immunocompetent individuals adequate protection. However, whether this level is enough to the tumor patients during chemotherapy remains unclear. PATIENT CONCERNS: A 58-year-old female lymphoma patient was admitted to our hospital for asthenia, nausea, vomiting, and abnormal liver function lasting over 1 week and diagnosed as acute hepatitis B. The patient just finished a course of chemotherapy with CHOP regimen and had recent record (78.61 IU/L) of HBsAb positive. The only risk of infection we could found was that the patient had received blood transfusion shortly after chemotherapy from a donor who was recovering from an asymptomatic acute HBV infection. INTERVENTION: The patient was administered with entecavir and glycyrrhizic acid agent, and then the disease was resolved successfully with hepatitis B surface antigen serological conversion. LESSONS: Tumor chemotherapy might have weakened the immune system of the patient and enhanced the body sensitivities to hepatitis B virus, then led to the infection. We concluded that HBsAb-positive status, at least "weakly positive," might not enough to provide protection for tumor patients on chemotherapy though this level was enough for health individuals and donors recuperating from subclinical acute hepatitis B might be another potential risk of HBV infection.
[Mh] Termos MeSH primário: Anticorpos Anti-Hepatite B/sangue
Antígenos de Superfície da Hepatite B/imunologia
Vírus da Hepatite B/imunologia
Hepatite B/imunologia
Linfoma/imunologia
[Mh] Termos MeSH secundário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Antivirais/uso terapêutico
Ciclofosfamida/uso terapêutico
Doxorrubicina/uso terapêutico
Feminino
Guanina/análogos & derivados
Guanina/uso terapêutico
Hepatite B/etiologia
Hepatite B/virologia
Seres Humanos
Linfoma/tratamento farmacológico
Linfoma/virologia
Meia-Idade
Prednisolona/uso terapêutico
Reação Transfusional
Vincristina/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Hepatitis B Antibodies); 0 (Hepatitis B Surface Antigens); 5968Y6H45M (entecavir); 5J49Q6B70F (Vincristine); 5Z93L87A1R (Guanine); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); 9PHQ9Y1OLM (Prednisolone)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171103
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008518


  8 / 9201 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29091567
[Au] Autor:Rencic J; Zhou M; Hsu G; Dhaliwal G
[Ad] Endereço:From the Department of Medicine, Tufts Medical Center, Boston (J.R., M.Z.); and the Department of Medicine, University of California, San Francisco, and the Medical Service, San Francisco Veterans Affairs Medical Center - both in San Francisco (G.H., G.D.).
[Ti] Título:Circling Back for the Diagnosis.
[So] Source:N Engl J Med;377(18):1778-1784, 2017 Nov 02.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Colecistite Aguda/diagnóstico
Hiperbilirrubinemia/etiologia
Esferocitose Hereditária/diagnóstico
[Mh] Termos MeSH secundário: Dor Abdominal/etiologia
Adulto
Colecistite Aguda/etiologia
Diagnóstico Diferencial
Vesícula Biliar/diagnóstico por imagem
Doença de Gilbert/complicações
Anticorpos Anti-Hepatite B/sangue
Seres Humanos
L-Lactato Desidrogenase/sangue
Masculino
Hepatopatia Gordurosa não Alcoólica/complicações
Obesidade/complicações
Esferocitose Hereditária/complicações
Vômito/etiologia
[Pt] Tipo de publicação:CASE REPORTS; CLINICAL CONFERENCE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis B Antibodies); EC 1.1.1.27 (L-Lactate Dehydrogenase)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171102
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMcps1701742


  9 / 9201 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28903797
[Au] Autor:Bassal R; Markovich MP; Weil M; Shinar E; Carmeli Y; Dan M; Sofer D; Mendelson E; Cohen D; Shohat T
[Ad] Endereço:Israel Center for Disease Control,Ministry of Health,Gertner Institute for Health Policy Research,Chaim Sheba Medical Center,Tel Hashomer,Ramat-Gan,Israel.
[Ti] Título:Prevalence of anti-hepatitis B surface antibodies among children and adolescents vaccinated in infancy and effect of booster dose administered within a pilot study.
[So] Source:Epidemiol Infect;145(14):2890-2895, 2017 10.
[Is] ISSN:1469-4409
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:We determined the prevalence of anti-hepatitis B surface antibodies (anti-HBs) among children and adolescents vaccinated for hepatitis B virus in infancy as part of the routine vaccination programme. A representative serum sample of the Israeli population age 0-19 was tested. In a separate pilot study, a booster dose of hepatitis B vaccine was administered to 31 candidates for national service, who were fully vaccinated in infancy and tested negative for hepatitis B surface antibodies at age 17-19 years and anti-HBs antibodies were assessed 8 weeks later. Of the 1273 samples tested, 631 (49·6%) were positive to anti-HBs antibodies. Seropositivity rates were 89·5% among infants aged 6-12 months and declined significantly with age to 20·7% at age 19 years. No differences in seropositivity rates were observed between Jews and Arabs, males and females and those born in Israel and in other countries. Seroconversion rate among the 31 individuals who received a booster dose was 90·3% (95% CI: 75·1-96·6%). We recommend a booster dose for healthcare personnel before starting to work at the health care facility.
[Mh] Termos MeSH primário: Anticorpos Anti-Hepatite B/sangue
Vacinas contra Hepatite B/administração & dosagem
Hepatite B/prevenção & controle
Imunização Secundária
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Estudos Transversais
Feminino
Hepatite B/epidemiologia
Hepatite B/virologia
Vírus da Hepatite B/imunologia
Seres Humanos
Lactente
Recém-Nascido
Israel/epidemiologia
Masculino
Projetos Piloto
Prevalência
Estudos Soroepidemiológicos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis B Antibodies); 0 (Hepatitis B Vaccines)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171125
[Lr] Data última revisão:
171125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170915
[St] Status:MEDLINE
[do] DOI:10.1017/S0950268817002126


  10 / 9201 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28886050
[Au] Autor:Davies J; Li SQ; Tong SY; Baird RW; Beaman M; Higgins G; Cowie BC; Condon JR; Davis JS
[Ad] Endereço:Department of Global and Tropical Health, Menzies School of Health Research, Darwin, Northern Territory, Australia.
[Ti] Título:Establishing contemporary trends in hepatitis B sero-epidemiology in an Indigenous population.
[So] Source:PLoS One;12(9):e0184082, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Indigenous populations globally are disproportionately affected by chronic hepatitis B virus (HBV) infection however contemporary sero-prevalence data are often absent. In the Indigenous population of the Northern Territory (NT) of Australia the unique C4 sub-genotype of HBV universally circulates. There are no studies of the sero-prevalence, nor the impact of the vaccination program (which has a serotype mismatch compared to C4), at a population-wide level. METHODS: We examined all available HBV serology results obtained from the three main laboratories serving NT residents between 1991 and 2011. Data were linked with a NT government database to determine Indigenous status and the most recent test results for each individual were extracted as a cross-sectional database including 88,112 unique individuals. The primary aim was to obtain a contemporary estimate of HBsAg positivity for the NT by Indigenous status. RESULTS: Based on all tests from 2007-2011 (35,633 individuals), hepatitis B surface antigen (HBsAg) positivity was 3·40% (95%CI 3·19-3·61), being higher in Indigenous (6·08%[5·65%-6·53%]) than non-Indigenous (1·56%[1·38%-1·76%]) Australians, p<0·0001. Birth cohort analysis showed HBsAg positivity fell over time for Indigenous people, with this decrease commencing prior to universal infant vaccination (which commenced in 1990), with an ongoing but slower rate of decline since 1990, (0·23% decrease per year versus 0·17%). CONCLUSIONS: HBsAg positivity is high in the NT, particularly in the Indigenous population. HBsAg positivity has fallen over time but a substantial part of this decrease is due to factors other than the universal vaccination program.
[Mh] Termos MeSH primário: Hepatite B/epidemiologia
Grupos Populacionais/estatística & dados numéricos
Vigilância da População
[Mh] Termos MeSH secundário: Adulto
Estudos Transversais
Feminino
Hepatite B/imunologia
Hepatite B/prevenção & controle
Hepatite B/virologia
Anticorpos Anti-Hepatite B/imunologia
Antígenos de Superfície da Hepatite B/imunologia
Vírus da Hepatite B/genética
Vírus da Hepatite B/imunologia
Seres Humanos
Programas de Imunização
Masculino
Meia-Idade
Northern Territory/epidemiologia
Prevalência
Estudos Retrospectivos
Estudos Soroepidemiológicos
Vacinação
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis B Antibodies); 0 (Hepatitis B Surface Antigens)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171018
[Lr] Data última revisão:
171018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170909
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0184082



página 1 de 921 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde